- Our Story
- In Memory
Pfizer, Johnson & Johnson Announce Discontinuation of Bapineuzumab (IV form) Studies
After failed second clinical trial, Bapineuzumab studies are dropped for patients with mild to moderate Alzheimer’s disease, as the drug was ineffective against clearing Abeta plaques in mild to moderate Alzheimer’s patients. The important consideration is to provide an Abeta clearing therapy far earlier in the disease process. Read Wall Street Journal Article here.